Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) Enterprise Value (2020 - 2025)

Tarsus Pharmaceuticals has reported Enterprise Value over the past 6 years, most recently at -$417.3 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$417.3 million for Q4 2025, down 340.07% from a year ago — trailing twelve months through Dec 2025 was -$417.3 million (down 340.07% YoY), and the annual figure for FY2025 was -$417.3 million, down 340.07%.
  • Enterprise Value for Q4 2025 was -$417.3 million at Tarsus Pharmaceuticals, down from -$401.8 million in the prior quarter.
  • Over the last five years, Enterprise Value for TARS hit a ceiling of -$94.8 million in Q4 2024 and a floor of -$417.3 million in Q4 2025.
  • Median Enterprise Value over the past 5 years was -$227.0 million (2022), compared with a mean of -$252.4 million.
  • Biggest five-year swings in Enterprise Value: surged 58.31% in 2024 and later tumbled 340.07% in 2025.
  • Tarsus Pharmaceuticals' Enterprise Value stood at -$171.8 million in 2021, then dropped by 26.31% to -$217.0 million in 2022, then fell by 4.8% to -$227.4 million in 2023, then surged by 58.31% to -$94.8 million in 2024, then crashed by 340.07% to -$417.3 million in 2025.
  • The last three reported values for Enterprise Value were -$417.3 million (Q4 2025), -$401.8 million (Q3 2025), and -$381.1 million (Q2 2025) per Business Quant data.